Clinical Trial Update: Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP [Phase 4]

View source ↗

Summary

A Phase 4 trial update shows that dupilumab, by blocking IL-4 receptor alpha, reduces Staphylococcus aureus colonization and increases microbial diversity in ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: University of Virginia | Conditions: Nasal Polyps, Staphylococcus Aureus | Phase 4 | Status: RECRUITING